LAM RESEARCH CORP (LRCX)
Sector: Information Technology
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Information Technology
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LRCX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LRCX | Director | 63 | ["Gen Digital", "Nutanix", "Option Care Health", "Industry Knowledge", "Customer/Deep Technology Knowledge", "Marketing, Disruptive Technology, and Strategy Experience", "Leadership Experience", "Finance Experience", "Global Business Experience", "M&A Experience", "Comparative Board/Governance Experience", "Cybersecurity Experience", "Human Capital Management Experience", "Risk Management Experience", "Manufacturing/Operations Experience", "Former Executive Vice President and Chief Financial Officer of Broadcom Corporation", "Financial expertise", "Knowledge of semiconductor industry", "Mergers and acquisitions experience", "Board governance experience", "Cybersecurity expertise"] | ["C/FE", "Audit", "Compensation and Human Resources", "Nominating and Governance"] | 2025 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| OPCH | Independent Director | 63 | ["Chief Financial Officer of Broadcom Inc., a Fortune 500 technology company (2007-2016)","President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a pharmaceutical manufacturing company (2005-2007)","Positions of increasing responsibility at Allergan Inc, a publicly-traded pharmaceutical manufacturing company, including as its Chief Financial Officer (1999-2005)","Vice President and Partner, The Boston Consulting Group, Inc. (1989-1999)","Significant business development and corporate strategy experience gained through executive leadership roles, including serving as chief executive officer and chief financial officer at multiple companies in the healthcare industry","Digital and technology experience gained through his leadership of the information technology department at a Fortune 500 technology company","Served in leadership roles on several public company boards, gaining valuable public company governance experience"] | ["Compensation Committee","Nominating and Corporate Governance Committee","Compensation","Quality, Technology and Compliance"] | 2026 |
| GEN | Director; Chair | 64 | ["Executive Vice President and Chief Financial Officer of Broadcom Corporation","CEO and President of Avanir Pharmaceuticals, Inc.","Various positions at Allergan, Inc., including Executive Vice President of Finance and Technical Operations","Ten years with The Boston Consulting Group, most recently serving as Vice President and Partner","audit committee financial expert"] | ["C","Audit (Chair)","Nominating & Governance","Audit Committee"] | 2026 |
| NTNX | Member; Director | 63 | ["Seasoned executive and public company director with more than three decades of experience in finance, operations, and strategic transformation", "Former Chief Financial Officer of Broadcom Corporation", "Led product advancement and operational transformation at Avanir Pharmaceuticals, Inc.", "Oversaw global manufacturing and technical operations at Allergan, Inc.", "Experienced in audit, compensation, finance, and cybersecurity committees", "Advised public companies on enterprise risk management and operational restructuring", "Deep expertise in IT infrastructure, cloud software, and cybersecurity oversight", "Knowledgeable in regulated industries and global markets with a focus on financial discipline"] | ["Security and Privacy Committee", "Audit", "Security and Privacy"] | 2025 |
| XRAY | Director | [] | ["Corporate Governance and Nominating Committee"] | 2024 | |
| MAC | Retired Executive Vice President and Chief Financial Officer of Broadcom Corporation; Chief Executive Officer | 61 | ["Retired Executive Vice President and Chief Financial Officer of Broadcom Corporation","Retail and/or Commercial Real Estate","Financial Literacy","Finance/Capital Markets/Investment","Business Operations","Risk Oversight/Management","International","Transactional Experience","ESG Oversight","Technology Expertise"] | ["Capital Allocation (Chair)","Compensation"] | 2024 |
| VRTX | Senior Vice President and Chief Financial Officer | 45 | ["Senior Vice President and Chief Financial Officer of Broadcom Corporation", "President and Chief Executive Officer of Avanir Pharmaceuticals", "Various positions at Allergan Inc. including Executive Vice President and Chief Financial Officer", "Vice President and Partner at the Boston Consulting Group"] | ["Audit and Finance Committee\u2014Chair", "Commercial Strategy Committee", "Corporate Governance and Nominating Committee"] | 2008 |
Biography sourced from the proxy statement filing.
Director since 2010 Age 63 Board Committees: Audit Chair since 2024, previously 2014-2020 Member: 2010-2014 Compensation and Human Resources Chair: 2020-2024 Nominating and Governance Member since 2019 Public company directorships in last five years: Nutanix, Inc. Option Care Health, Inc. Gen Digital Inc. The Macerich Company (former) Dentsply Sirona Inc. (former) Experience Eric K. Brandt is the former Executive Vice President and Chief Financial Officer of Broadcom Corporation, a global supplier of semiconductor devices, a position he held from March 2007 until its merger with Avago Technologies Limited in February 2016. From September 2005 to March 2007, Mr. Brandt served as President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a pharmaceutical company. Prior to Avanir Pharmaceuticals, Mr. Brandt was Executive Vice President-Finance and Technical Operations and Chief Financial Officer of Allergan Inc., a global specialty pharmaceutical company, where he also held a number of other senior positions following his arrival there in May 1999. Mr. Brandt has served as a member of the board of directors of: Nutanix, Inc., a cloud computing company, since May 2025, where he serves as a member of the audit committee; Option Care Health, Inc., a health provider of home and alternate site infusion services, since May 2024, where he serves as a member of the compensation committee and the regulatory and compliance committee, and has served as a member of the finance and investment committee; Gen Digital Inc. (formerly NortonLifeLock, Inc.), a consumer cyber security provider, since February 2020, where he is the chair of the audit committee and serves on the nominating and governance committee; and Altaba Inc. (formerly Yahoo! Inc.), a private company that remained, and was subsequently renamed, following the completion of Yahoo! s sale of its operating businesses in June 2017 (and which is in the process of a stockholder approved plan of dissolution and liquidation), since its inception, where he is the chair of the audit committee, and has served as chair of the board, chair of the nominating and governance committee, and a member of the compensation committee. He previously served on the board of directors of: The Macerich Company, a real estate investment trust focused on retail real estate, from June 2018 to June 2025, where he was the chair of the capital allocation committee and a member of the compensation committee; Dentsply Sirona Inc. (formerly Dentsply International, Inc.), a manufacturer and distributor of dental product solutions, from 2004 to 2024, where he was the non-executive chair of the board, chair of the executive committee, and served as a member of the corporate governance and nominating committee, the human resources committee, and the audit and finance committee; MC10, Inc., a privately-held medical device Internet of Things (IoT) company, from March 2016 until February 2018, where he was chair of the compensation committee and governance committee; Yahoo! Inc., a digital information discovery company, from March 2016 to June 2017, where he was chair of the board and chair of the audit and finance committee; Vertex Pharmaceuticals, Inc., a pharmaceutical company, from 2002 to 2009, where he was chair of the audit committee, and a member of the nominating and governance committee; and Avanir Pharmaceuticals from 2005 to 2007. Mr. Brandt earned an M.B.A. degree from the Harvard Graduate School of Business and a B.S. degree in chemical engineering from the Massachusetts Institute of Technology. He has competed the NYU Law Nasdaq Cyber Scholar Program and the U.S. Secret Service and the National Association of Corporate Directors Cybersecurity Program. Qualifications The Board has concluded that Mr. Brandt should serve as a director of the Company because of his financial expertise including as a former chief financial officer of a publicly traded company that is a customer of our customers; his knowledge of and experience in the semiconductor industry and other technology industries; his mergers and acquisitions experience; his board governance experience from service on other public company boards, including as an audit committee member and chair, a compensation committee member, and a nominating and governance committee member and chair; and his cybersecurity expertise. Key Skills and Experiences Industry Knowledge Customer/Deep Technology Knowledge Leadership Experience Finance Experience Global Business Experience M&A Experience Comparative Board/Governance Experience Cybersecurity Experience Human Capital Management Experience Risk Management Experience Manufacturing/Operations Experience